AstraZeneca's baxdrostat was approved by the FDA in May 2026 for treatment-resistant hypertension following positive Phase 3 BaxHTN trial results.

Drug pricing and affordability, FDA drug approvals, clinical trial design, drug shortages, insurer coverage, pharmaceutical regulation, and medication access.

Drug pricing policy, insurance prior authorization, and essential drug shortages affecting medication affordability and access.